Kathleen M Schmainda1,2, Melissa A Prah1, Helga Marques3, Eunhee Kim4, Daniel P Barboriak5, Jerrold L Boxerman6. 1. Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wisconsin. 2. Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island. 4. Merck Research Laboratories, Kenilworth, New Jersey. 5. Duke University Medical Center, Durham, North Carolina. 6. Department of Diagnostic Imaging, Rhode Island Hospital, and Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Abstract
BACKGROUND: In Radiation Therapy Oncology Group (RTOG) 0825, a phase III trial of standard therapy with bevacizumab or without (placebo) in newly diagnosed glioblastoma, 44 patients underwent dynamic contrast enhanced (DCE) and/or dynamic susceptibility contrast (DSC) MRI in the American College of Radiology Imaging Network (ACRIN) trial 6686. The association between early changes in relative cerebral blood volume (rCBV) and volume transfer constant (Ktrans) with overall survival (OS) was evaluated. METHODS: MRI was performed at postop baseline (S0), immediately before (S1), 1 day after (S2), and 7 weeks after (S3) bevacizumab or placebo initiation. Mean normalized and standardized rCBV (nRCBV, sRCBV) and Ktrans were measured within contrast-enhancing lesion. Wilcoxon rank sum tests compared parameter changes from S1-S2 and S1-S3. Association with OS and progression-free survival (PFS) were determined using Kaplan-Meier and log-rank tests. Treatment response for groups stratified by pretreatment nRCBV (S0, S1) was explored. The intraclass correlation coefficient and repeatability coefficient for the placebo arm (S1-S2) were used to assess repeatability. RESULTS: Evaluable were 27-36 datasets per time point. Significant differences between treatment arms were found for changes in nRCBV and sRCBV from S1-S2 and S1-S3, and in Ktrans for S1-S3. Improved PFS (P = 0.05) but not OS (P = 0.46) was observed. High pretreatment rCBV predicted improved OS for bevacizumab-treated patients. Based on the intraclass correlation coefficient, sRCBV (0.92) was more repeatable than nRCBV (0.71) and Ktrans (0.75), consistent with repeatability coefficient values. CONCLUSIONS: Bevacizumab significantly changes rCBV but not Ktrans as early as 1 day posttreatment in newly diagnosed glioblastoma unrelated to outcomes. Improvements in clinical trial design to maximize rCBV benefit are indicated.
BACKGROUND: In Radiation Therapy Oncology Group (RTOG) 0825, a phase III trial of standard therapy with bevacizumab or without (placebo) in newly diagnosed glioblastoma, 44 patients underwent dynamic contrast enhanced (DCE) and/or dynamic susceptibility contrast (DSC) MRI in the American College of Radiology Imaging Network (ACRIN) trial 6686. The association between early changes in relative cerebral blood volume (rCBV) and volume transfer constant (Ktrans) with overall survival (OS) was evaluated. METHODS: MRI was performed at postop baseline (S0), immediately before (S1), 1 day after (S2), and 7 weeks after (S3) bevacizumab or placebo initiation. Mean normalized and standardized rCBV (nRCBV, sRCBV) and Ktrans were measured within contrast-enhancing lesion. Wilcoxon rank sum tests compared parameter changes from S1-S2 and S1-S3. Association with OS and progression-free survival (PFS) were determined using Kaplan-Meier and log-rank tests. Treatment response for groups stratified by pretreatment nRCBV (S0, S1) was explored. The intraclass correlation coefficient and repeatability coefficient for the placebo arm (S1-S2) were used to assess repeatability. RESULTS: Evaluable were 27-36 datasets per time point. Significant differences between treatment arms were found for changes in nRCBV and sRCBV from S1-S2 and S1-S3, and in Ktrans for S1-S3. Improved PFS (P = 0.05) but not OS (P = 0.46) was observed. High pretreatment rCBV predicted improved OS for bevacizumab-treated patients. Based on the intraclass correlation coefficient, sRCBV (0.92) was more repeatable than nRCBV (0.71) and Ktrans (0.75), consistent with repeatability coefficient values. CONCLUSIONS: Bevacizumab significantly changes rCBV but not Ktrans as early as 1 day posttreatment in newly diagnosed glioblastoma unrelated to outcomes. Improvements in clinical trial design to maximize rCBV benefit are indicated.
Authors: Kevin Leu; Jerrold L Boxerman; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; Timothy F Cloughesy; Benjamin M Ellingson Journal: J Magn Reson Imaging Date: 2016-03-12 Impact factor: 4.813
Authors: Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Jeffrey M Rogg; Ronald L Wolf; Suyash Mohan; Helga Marques; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Robert J Harris; Timothy F Cloughesy; Anthony J Hardy; Linda M Liau; Whitney B Pope; Phioanh L Nghiemphu; Albert Lai; Benjamin M Ellingson Journal: J Neurooncol Date: 2015-03-15 Impact factor: 4.130
Authors: Tracy T Batchelor; Elizabeth R Gerstner; Kyrre E Emblem; Dan G Duda; Jayashree Kalpathy-Cramer; Matija Snuderl; Marek Ancukiewicz; Pavlina Polaskova; Marco C Pinho; Dominique Jennings; Scott R Plotkin; Andrew S Chi; April F Eichler; Jorg Dietrich; Fred H Hochberg; Christine Lu-Emerson; A John Iafrate; S Percy Ivy; Bruce R Rosen; Jay S Loeffler; Patrick Y Wen; A Greg Sorensen; Rakesh K Jain Journal: Proc Natl Acad Sci U S A Date: 2013-11-04 Impact factor: 11.205
Authors: Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-22 Impact factor: 4.254
Authors: A F Cardona; L Rojas; B Wills; A Ruiz-Patiño; L Abril; F Hakim; E Jiménez; N Useche; S Bermúdez; J A Mejía; J F Ramón; H Carranza; C Vargas; J Otero; P Archila; J Rodríguez; J Rodríguez; J Behaine; D González; J Jacobo; H Cifuentes; O Feo; P Penagos; D Pineda; L Ricaurte; L E Pino; C Vargas; J C Marquez; M I Mantilla; L D Ortiz; C Balaña; R Rosell; Z L Zatarain-Barrón; O Arrieta Journal: Clin Transl Oncol Date: 2019-02-23 Impact factor: 3.340
Authors: Otto M Henriksen; María Del Mar Álvarez-Torres; Patricia Figueiredo; Gilbert Hangel; Vera C Keil; Ruben E Nechifor; Frank Riemer; Kathleen M Schmainda; Esther A H Warnert; Evita C Wiegers; Thomas C Booth Journal: Front Oncol Date: 2022-03-03 Impact factor: 5.738
Authors: Ryan T Woodall; Prativa Sahoo; Yujie Cui; Bihong T Chen; Mark S Shiroishi; Cristina Lavini; Paul Frankel; Margarita Gutova; Christine E Brown; Jennifer M Munson; Russell C Rockne Journal: Neurooncol Adv Date: 2021-11-22
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639
Authors: Thomas C Booth; Evita C Wiegers; Esther A H Warnert; Kathleen M Schmainda; Frank Riemer; Ruben E Nechifor; Vera C Keil; Gilbert Hangel; Patrícia Figueiredo; Maria Del Mar Álvarez-Torres; Otto M Henriksen Journal: Front Oncol Date: 2022-02-28 Impact factor: 5.738